Comparing Amarillo Biosciences (OTCMKTS:AMAR) & Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) and Amarillo Biosciences (OTCMKTS:AMAR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Insider and Institutional Ownership

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by insiders. Comparatively, 34.4% of Amarillo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Corcept Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.

Profitability

This table compares Corcept Therapeutics and Amarillo Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	22.35%	24.54%	20.24%
Amarillo Biosciences	-41,453.98%	N/A	-574.29%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Corcept Therapeutics and Amarillo Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0	0	5	0	3.00
Amarillo Biosciences	0	0	0	0	0.00

Corcept Therapeutics presently has a consensus target price of $88.25, indicating a potential upside of 44.13%. Given Corcept Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Corcept Therapeutics is more favorable than Amarillo Biosciences.

Earnings and Valuation

This table compares Corcept Therapeutics and Amarillo Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$628.56 million	10.21	$106.14 million	$1.26	48.60
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A

Corcept Therapeutics has higher revenue and earnings than Amarillo Biosciences.

Summary

Corcept Therapeutics beats Amarillo Biosciences on 10 of the 11 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.